JP Morgan Chase
TEVA icon

JP Morgan Chase’s Teva Pharmaceuticals TEVA Stock Holding History

JP Morgan Chase’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$233M Buy
6,981,234
+218,490
+3% +$7.28M 0.01% 698
2026
Q1 		$192M Buy
6,762,744
+5,568,294
+466% +$179M 0.01% 712
2025
Q4 		$37.3M Sell
1,194,450
-190,660
-14% -$4.7M ﹤0.01% 1563
2025
Q3 		$28M Sell
1,385,110
-356,346
-20% -$6.26M ﹤0.01% 1828
2025
Q2 		$29.2M Sell
1,741,456
-372,515
-18% -$6.01M ﹤0.01% 1678
2025
Q1 		$32.5M Sell
2,113,971
-875,378
-29% -$15.6M ﹤0.01% 1555
2024
Q4 		$65.9M Buy
2,989,349
+967,388
+48% +$17.6M ﹤0.01% 1151
2024
Q3 		$36.4M Sell
2,021,961
-3,010,555
-60% -$52.7M ﹤0.01% 1544
2024
Q2 		$81.8M Buy
5,032,516
+2,024,898
+67% +$31.2M 0.01% 1007
2024
Q1 		$42.4M Buy
3,007,618
+895,238
+42% +$11.3M ﹤0.01% 1383
2023
Q4 		$22.1M Buy
2,112,380
+1,152,610
+120% +$10.8M ﹤0.01% 1774
2023
Q3 		$9.79M Sell
959,770
-152,617
-14% -$1.42M ﹤0.01% 2259
2023
Q2 		$8.38M Sell
1,112,387
-159,513
-13% -$1.29M ﹤0.01% 2443
2023
Q1 		$11.3M Buy
1,271,900
+660,539
+108% +$6.53M ﹤0.01% 2175
2022
Q4 		$5.58M Buy
611,361
+6,711
+1% +$58.6K ﹤0.01% 2734
2022
Q3 		$4.88M Buy
604,650
+66,669
+12% +$590K ﹤0.01% 2759
2022
Q2 		$4.05M Sell
537,981
-7,310
-1% -$63.7K ﹤0.01% 2973
2022
Q1 		$5.12M Sell
545,291
-68,505
-11% -$572K ﹤0.01% 2982
2021
Q4 		$4.92M Buy
613,796
+23,384
+4% +$211K ﹤0.01% 3079
2021
Q3 		$5.75M Sell
590,412
-1,283,385
-68% -$12M ﹤0.01% 2920
2021
Q2 		$18.6M Sell
1,873,797
-1,575,042
-46% -$16.7M ﹤0.01% 1908
2021
Q1 		$39.8M Buy
3,448,839
+572,952
+20% +$6.57M 0.01% 1273
2020
Q4 		$27.8M Sell
2,875,887
-1,409,275
-33% -$13.5M ﹤0.01% 1394
2020
Q3 		$37.9M Buy
4,285,162
+1,505,871
+54% +$15.9M 0.01% 1116
2020
Q2 		$34.3M Sell
2,779,291
-802,265
-22% -$9.07M 0.01% 1050
2020
Q1 		$32.2M Sell
3,581,556
-907,417
-20% -$9.3M 0.01% 1001
2019
Q4 		$44M Buy
4,488,973
+2,110,216
+89% +$18.8M 0.01% 1034
2019
Q3 		$16.4M Sell
2,378,757
-1,884,322
-44% -$14.4M ﹤0.01% 1754
2019
Q2 		$38.7M Buy
4,263,079
+1,875,195
+79% +$22.6M 0.01% 1111
2019
Q1 		$37.4M Buy
2,387,884
+492,850
+26% +$8.69M 0.01% 1121
2018
Q4 		$29.2M Sell
1,895,034
-186,515
-9% -$3.82M 0.01% 1204
2018
Q3 		$44.8M Sell
2,081,549
-2,135,429
-51% -$49.6M 0.01% 1077
2018
Q2 		$103M Sell
4,216,978
-16,173,043
-79% -$330M 0.02% 651
2018
Q1 		$348M Buy
20,390,021
+18,050,787
+772% +$352M 0.07% 282
2017
Q4 		$44.3M Buy
2,339,234
+318,828
+16% +$4.8M 0.01% 1051
2017
Q3 		$34.7M Sell
2,020,406
-5,187,293
-72% -$117M 0.01% 1137
2017
Q2 		$239M Sell
7,207,699
-575,544
-7% -$17.8M 0.05% 354
2017
Q1 		$250M Sell
7,783,243
-1,144,919
-13% -$39.1M 0.06% 338
2016
Q4 		$324M Sell
8,928,162
-1,767,337
-17% -$70.6M 0.08% 266
2016
Q3 		$492M Buy
10,695,499
+3,424,656
+47% +$179M 0.12% 194
2016
Q2 		$365M Buy
7,270,843
+1,664,452
+30% +$88.6M 0.09% 248
2016
Q1 		$300M Buy
5,606,391
+729,668
+15% +$42.8M 0.08% 284
2015
Q4 		$320M Buy
4,876,723
+927,447
+23% +$57.3M 0.08% 270
2015
Q3 		$223M Sell
3,949,276
-591,802
-13% -$38.4M 0.06% 336
2015
Q2 		$268M Buy
4,541,078
+1,074,001
+31% +$66.3M 0.06% 330
2015
Q1 		$216M Sell
3,467,077
-42,379
-1% -$2.46M 0.05% 395
2014
Q4 		$202M Sell
3,509,456
-434,387
-11% -$24.2M 0.05% 411
2014
Q3 		$212M Buy
3,943,843
+130,325
+3% +$6.9M 0.05% 395
2014
Q2 		$200M Buy
3,813,518
+322,446
+9% +$16.5M 0.05% 386
2014
Q1 		$184M Buy
3,491,072
+222,880
+7% +$10.3M 0.05% 393
2013
Q4 		$131M Sell
3,268,192
-210,791
-6% -$8.3M 0.04% 448
2013
Q3 		$131M Sell
3,478,983
-333,610
-9% -$13M 0.04% 455
2013
Q2 		$149M Buy
+3,812,593
New +$148M 0.05% 387

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

JP Morgan Chase's TEVA Position: Q2 2026 in Review

JP Morgan Chase increased its Teva Pharmaceuticals (TEVA) stake by 3.2% in Q2 2026, buying an estimated $7.28M and bringing the position to 6,981,234 shares worth $233M. The position accounts for 0.01% of the portfolio, ranked #698.

JP Morgan Chase first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $492M in Q3 2016. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • JP Morgan Chase held 6,981,234 shares of Teva Pharmaceuticals worth $233M as of Q2 2026.
  • JP Morgan Chase bought 218,490 Teva Pharmaceuticals shares in Q2 2026, an estimated $7.28M.
  • Teva Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #698 holding.
  • JP Morgan Chase first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Teva Pharmaceuticals position peaked at $492M in Q3 2016.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.